HUMAN CHANGE SYSTEMS

Brand Owner Address Description
HUMANCHANGESYSTEMS NAVITENT, INC. 221 Main Street Unit 2061 Los Altos CA 94023 HUMAN CHANGE SYSTEMS;Platform as a service (PAAS) featuring computer software platforms using artificial intelligence augmentation for program delivery, management, and onboarding, for providing educational content and healthcare information, for assuring user accountability, and for providing analytics for use in social impact programs and programs for bettering the common good; Software as a service (SAAS) services featuring non-downloadable software using artificial intelligence augmentation for program delivery, management, and onboarding, for providing educational content and healthcare information, for assuring user accountability, and for providing analytics for use in social impact programs and programs for bettering the common good; Platform as a service (PAAS) and software as a service (SAAS) featuring computer software platforms and computer software for allowing users to perform e-commerce electronic business transactions via a global computer network; Platform as a service (PAAS) and software as a service (SAAS) featuring computer software platforms and computer software for assisting digital aided situational awareness and connection between users;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-? (TNF-?), human tissue factor (TF), human ?4?7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor ?-chain (TAC) for diagnostic and therapeutic applications.